Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
EVFM Evofem Biosciences	$0.01 +4.3%	$0.01	$0.01 ▼ $0.02	$1.15M	-0.99	404,013 shs	1.96 million shs
NCNA NuCana	$4.15 -8.8%	$13.43	$4.12 ▼ $2,158.00	$125K	1.4	541,801 shs	518,797 shs
OGEN Oragenics	$1.19 +3.5%	$2.32	$1.03 ▼ $57.60	$979K	0.65	335,908 shs	83,257 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
EVFM Evofem Biosciences	0.00%	0.00%	+1.09%	+2.20%	-1.06%
NCNA NuCana	-3.40%	-43.69%	-50.44%	-57.40%	-99.33%
OGEN Oragenics	-1.71%	-12.21%	-18.44%	-80.30%	-98.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	1.738 of 5 stars	0.0	5.0	0.0	4.8	2.5	0.0	0.0
NCNA NuCana	3.4037 of 5 stars	3.3	4.0	0.0	0.0	2.6	2.5	1.3
OGEN Oragenics	0.1211 of 5 stars	0.0	4.0	0.0	0.0	0.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	0.00	N/A	N/A	N/A
EVFM Evofem Biosciences	0.00	N/A	N/A	N/A
NCNA NuCana	2.50	Moderate Buy	$5,000.00	120,381.93% Upside
OGEN Oragenics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
EVFM Evofem Biosciences	$11.39M	0.10	N/A	N/A	($2.64) per share	0.00
NCNA NuCana	N/A	N/A	N/A	N/A	$267.86 per share	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	$0.61 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	∞	N/A	N/A	-8,454.87%	-121.60%	N/A
EVFM Evofem Biosciences	$52.98M	-$0.05	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
NCNA NuCana	-$24.28M	-$1,404.00	N/A	N/A	N/A	N/A	-319.85%	-88.55%	8/21/2025 (Estimated)
OGEN Oragenics	-$20.66M	-$21.42	N/A	∞	N/A	N/A	-2,087.95%	-486.56%	N/A

Latest NCNA, ASLN, OGEN, and EVFM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/2/2025	Q1 2025	NCNA NuCana	-$2.5820	-$126.00	-$123.4180	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
OGEN Oragenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
EVFM Evofem Biosciences	N/A	0.11	0.09
NCNA NuCana	N/A	1.25	1.25
OGEN Oragenics	N/A	1.93	1.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
EVFM Evofem Biosciences	0.22%
NCNA NuCana	44.00%
OGEN Oragenics	18.71%

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
EVFM Evofem Biosciences	0.01%
NCNA NuCana	31.20%
OGEN Oragenics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	Optionable
EVFM Evofem Biosciences	120	118.66 million	113.12 million	Not Optionable
NCNA NuCana	30	30,000	21,000	Not Optionable
OGEN Oragenics	5	823,000	10.98 million	N/A

NCNA, ASLN, OGEN, and EVFM Headlines

Recent News About These Companies

Oragenics (NYSE:OGEN) Stock Price Down 1.7% - Should You Sell?

August 14 at 3:47 AM | americanbankingnews.com

Oragenics Q2 2025 Shareholder Update

August 11 at 8:45 AM | globenewswire.com

Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

July 31, 2025 | finance.yahoo.com

Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

July 16, 2025 | globenewswire.com

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - Seeking Alpha

July 3, 2025 | seekingalpha.com

Oragenics stock tumbles after announcing $20 million preferred stock offering

July 2, 2025 | investing.com

Oragenics Completes Approximately $16.5 Million Offering

July 2, 2025 | globenewswire.com

Sarasota biotech company announces $20M public offering

July 2, 2025 | businessobserverfl.comB

Oragenics shares plunge following announcement of $20 million preferred stock sale

July 1, 2025 | msn.com

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

July 1, 2025 | globenewswire.com

Oragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

June 11, 2025 | nasdaq.com

Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium

June 10, 2025 | finance.yahoo.com

Oragenics Inc.

June 4, 2025 | wsj.com

Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split

May 29, 2025 | finance.yahoo.com

Oragenics Hosts Neurotrauma Medicine Webinar Presentation

May 20, 2025 | tipranks.com

Oragenics gains Australia’s nod for concussion therapy trial

May 15, 2025 | uk.investing.com

Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment

May 14, 2025 | nasdaq.com

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025 | globenewswire.com

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion ...

May 12, 2025 | gurufocus.com

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

May 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NCNA, ASLN, OGEN, and EVFM Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 08/13/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Evofem Biosciences NASDAQ:EVFM

$0.0097 +0.00 (+4.30%)

As of 03:59 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

NuCana NASDAQ:NCNA

$4.15 -0.40 (-8.79%)

Closing price 04:00 PM Eastern

Extended Trading

$4.17 +0.02 (+0.48%)

As of 05:48 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Oragenics NYSE:OGEN

$1.19 +0.04 (+3.48%)

Closing price 04:00 PM Eastern

Extended Trading

$1.16 -0.02 (-2.10%)

As of 05:32 PM Eastern

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time